FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know
An FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than among those taking placebos or other diabetes medications.
We haven't written up this one. Live Mint has the full story — the link below goes straight to it.